A wound debridement claim may look accurate until a payer asks one decisive question: What tissue was actually removed, and how many square centimeters were treated? When the note cannot answer both, payment slows, documentation requests begin, and a seemingly routine service moves deeper into accounts receivable.
The stakes are higher in 2026, making it critical to understand how to improve wound care reimbursement. CMS changed how Medicare pays for skin-substitute products, while federal oversight intensified after annual Medicare Part B spending on these products exceeded $10 billion by the end of 2024. Resilient MBS recommends managing coding, product selection, documentation, authorization, and payment posting as one connected process rather than treating reimbursement as a claim-submission issue alone.
https://resilientmbs.com/icd-10-dental-billing-codes/
The deepest visible tissue does not automatically determine the debridement code. Medicare contractors expect the record to show the deepest level of tissue actually removed, the method used, and the area debrided.
Resilient MBS recommends distinguishing selective debridement codes 97597–97598 from surgical debridement codes 11042–11047 through the procedure note itself. A wound that exposes muscle does not support muscle-level debridement when only subcutaneous tissue was removed.
The note should clearly document:
Resilient MBS advises billing teams to pause claim release when these elements conflict. A timely provider query protects more revenue than a weak claim followed by an appeal.
https://resilientmbs.com/internal-medicine/
Debridement reimbursement depends on both depth and surface area. Medicare guidance states that wounds debrided to the same depth may have their treated areas added together, but areas from different depths should not be combined into one total.
Resilient MBS recommends recording each wound separately before calculating billable units. This prevents missed add-on codes, unsupported units, and accidental overbilling.
| Revenue leak | Weak approach | Better reimbursement control |
|---|---|---|
| Debridement depth | Code from the deepest visible tissue | Code the deepest tissue actually removed |
| Wound area | Use the total wound size automatically | Document the surface area actually debrided |
| Multiple wounds | Combine every wound into one total | Sum only wounds treated to the same depth |
| Procedure support | Record “wound cleaned” | Identify devitalized tissue, method, and tissue removed |
| Progress | Repeat identical notes | Document measurable response or explain why treatment changed |
Resilient MBS uses this comparison during focused billing audits because many reimbursement problems begin before the code reaches the claim.
https://resilientmbs.com/medical-billing-services-in-roswell/
For 2026, CMS finalized a major shift in skin-substitute reimbursement. Medicare now treats covered skin-substitute products as incident-to supplies when used with a covered application procedure in nonfacility physician settings and hospital outpatient departments. CMS also aligned products by FDA regulatory category and established a single payment rate for 2026 based on the highest average among those categories.
Resilient MBS recommends updating:
A product that produced favorable reimbursement under the previous methodology may create a financial loss under the 2026 structure. Resilient MBS advises practices to compare acquisition cost with the current payer allowance before use, while keeping clinical appropriateness and coverage criteria central to the decision.
OIG found that Medicare skin-substitute spending rose from roughly $400 million to nearly $3 billion per quarter within two years, driven by increased use and higher prices. That growth has placed these claims under heightened review.
Resilient MBS recommends documenting more than the product name and wound dimensions. The record should establish:
Coverage varies by Medicare Administrative Contractor and payer. Resilient MBS therefore recommends reviewing the applicable LCD, billing article, product status, and payer authorization rules before treatment begins.
Routine removal of secretions, dressing changes, washing, or cleansing does not automatically support a billable debridement service. Medicare guidance requires removal of devitalized or contaminated tissue and documentation supporting medical necessity.
Resilient MBS recommends matching the procedure language to the clinical work. Avoid vague phrases such as “wound care performed” when the claim reports an active debridement code.
Billing professionals can also review Resilient MBS resources covering CPT code 97597 and CPT code 11042 when building internal coding references.
Local anesthesia used by the practitioner performing debridement is generally included in the debridement reimbursement. Certain routine dressings, supplies, and treatment components may also be included depending on the service and setting.
Resilient MBS recommends checking current NCCI edits, payer bundling rules, place of service, and coverage articles before adding separate supply or procedure lines. Do not use modifier 59 or another modifier merely to bypass an edit.
Key takeaway: Every additional charge needs an independent service, a permissible coding relationship, and documentation that proves why separate reporting is appropriate.
Active coverage does not confirm payment for every wound-care service. Resilient MBS recommends verifying the procedure, product, diagnosis, provider, setting, frequency limit, and authorization requirement before treatment.
A strong verification record includes:
This step is especially important for advanced wound products, negative-pressure therapy, repeated debridement, and home-based services.
Texas Medicare providers face an added 2026 issue. Texas participates in CMS’s WISeR Model, which applies technology-supported prior authorization or post-service prepayment review to selected Original Medicare services. The model includes certain skin and tissue substitute services when the applicable LCD is active.
Resilient MBS recommends that Texas billing teams confirm whether the code, setting, and service fall within WISeR before treatment. Providers may choose prior authorization or proceed to post-service prepayment review, but missing documentation can delay payment either way.
Texas Medicaid also updated office-setting skin-substitute reimbursement effective June 1, 2026. TMHP separately states that facility-setting skin-substitute products are included in the application service and are not separately reimbursed.
Virginia Original Medicare claims fall under Palmetto GBA’s Jurisdiction M. Palmetto advises that surgical debridement claims should document the tissue removed, surface area after debridement, wound characteristics, procedure details, and response to treatment.
Resilient MBS recommends separate workflows for Virginia Medicare, Virginia Medicaid fee-for-service, and Cardinal Care managed-care plans. DMAS provides tools for checking eligibility, authorization, claim status, payment, and service limits, but managed-care billing requirements can differ.
A paid claim may still be underpaid. Resilient MBS recommends comparing each payment with the expected allowed amount, contractual adjustment, product reimbursement, patient responsibility, and secondary-payer requirement.
Track these metrics monthly:
Resilient MBS also recommends sorting variances by payer, provider, wound type, code, product, and location. One overall collection rate can hide a serious problem affecting a specific payer or treatment category.
Before submitting a wound-care claim, Resilient MBS recommends confirming:
Practices needing deeper support can review Resilient MBS’s wound care billing services, which include claim processing, denial support, reimbursement review, and billing-process analysis.
Resilient MBS recommends improving documentation, coding debridement by the tissue actually removed, verifying coverage before treatment, monitoring 2026 skin-substitute payment changes, and auditing paid claims for underpayments.
The record should identify the wound, measurements, tissue removed, debridement depth, method, area treated, patient response, medical necessity, and treatment plan. Medicare contractors may request both pre- and post-debridement measurements.
Add the treated surface areas of wounds debrided to the same depth. Do not combine wound areas treated at different depths.
CMS moved covered skin substitutes to an incident-to supply payment approach and established a grouped single payment rate for 2026 across the relevant FDA categories.
Some Original Medicare skin-substitute services in Texas may be subject to the WISeR prior-authorization or prepayment-review process when included under an active applicable LCD. Verify the current operational guide and code list.
Resilient MBS recommends weekly reviews of denials, rejections, and authorization failures, plus monthly coding and payment-variance audits. Additional audits should follow payer changes, new products, or repeated documentation problems.